Colorectal cancer (CRC) is the third most common cause of death due to cancer across the world: fewer than 20% of patients survive beyond 5 years after a diagnosis of metastatic CRC (mCRC). For patients with unresectable mCRC, chemotherapy and biological therapy form the main line of treatment, and numerous options for first-line combination chemotherapeutic regimens have been used across the world, the most frequently used ones being FOLFOX, FOLFIRI, and CAPOX.
Our client was interested to understand the safety and efficacy of first line (including subsequent therapies) in mCRC. For this project, we extracted data pertaining to the baseline patient characteristics from around 70 studies that were identified as containing relevant information for the project, including patient demographics, performance status, current disease status, mutational status, mutational status, prior treatments, and comorbidities. Therapy area: Oncology